Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa Study of hNPC01 Cell Transplantation for Hemiplegic Sequelae After Ischemic Stroke
ChiCTR2500108390Phase 2Not yet recruiting
- Sponsor
- Seventh Medical Center of the People's Liberation Army General Hospital Neurosurgery Department
- Start
- Aug 2025
- Modality
- iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised trial of hNPC01 in ischemic stroke and hemiplegia (4 arms), sponsored by Seventh Medical Center of the People's Liberation Army General Hospital Neurosurgery Department. Primary endpoint: Safety and tolerance 6 months after cell implantation. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
hNPC01
03
Conditions
ischemic strokehemiplegia
Beyond the preview
Go deeper on ChiCTR2500108390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500108390.